AKT1 and glioma: Dose-dependently decreased expressions of TAGLN2, p-PI3K and p-Akt in Sal A-treated U87 cells suggested that Sal A treatment inactivated TAGLN2/PI3K/Akt pathway in glioma cells (Figure 4).